Quick Takeaways
- Foresite Capital Fund IV, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL).
- Disclosed ownership: 9.2%.
- Date of event: 31 Mar 2025.
Quoteable Key Fact
"Foresite Capital Fund IV, L.P. disclosed 9.2% ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL) on 31 Mar 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Foresite Capital Fund IV, L.P. | 5.4% | 16,007,999 | 16,007,999 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Management IV, LLC | 5.4% | 16,007,999 | 16,007,999 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| Foresite Capital Fund V, L.P. | 2.8% | 8,133,047 | 8,133,047 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Management V, LLC | 2.8% | 8,133,047 | 8,133,047 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| Foresite Capital Opportunity Fund V, L.P. | 1% | 3,020,846 | 3,020,846 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member of the General Partner | |
| Foresite Capital Opportunity Management V, LLC | 1% | 3,020,846 | 3,020,846 | 0 | /s/ James Tananbaum | James Tananbaum, Managing Member | |
| James B. Tananbaum | 9.2% | 27,161,892 | 27,161,892 | 0 | /s/ James Tananbaum | James Tananbaum |